1. Introduction {#sec1}
===============

Coronary artery disease (CAD) is the most common cardiovascular disease. It is caused by ischemia and hypoxia \[[@B1]\] due to the formation of plaque which hardens and narrows the coronary arteries, and it is the major cause of death worldwide, accounting for nearly 7 million deaths annually \[[@B2]\]. CAD is considered as the most common cause of death among both men and women over the age of 50 \[[@B3]\]. Environmental factors associated with CAD include obesity, alcohol intake, smoking, diabetes, hypertension, and dyslipidemia \[[@B4]\]. In addition, genetic factors contribute to the occurrence and development of CAD. Elevated triglyceride (TG) and low HDL-C levels are characteristic of dyslipidemia, which is associated with high risk of cardiovascular events \[[@B4], [@B5]\]. The apolipoprotein A5 (apoAV) encoded by the APOA5 gene \[[@B6], [@B7]\] that belongs to the APOA1/C3/A4/A5 gene cluster on chromosome 11q23 regulates lipoprotein lipase (LPL) activity \[[@B8], [@B9]\]. New physiological roles of apoAV have been recently elucidated, such as control of chylomicron production in the intestine and TG accumulation in adipose tissue \[[@B10]\]. Epidemiological studies showed a strong correlation between increased TG concentrations and the elevation of coronary artery disease risk and more importantly with all-cause mortality \[[@B3], [@B11]--[@B14]\]. Moreover, the deficiency of the endogenous APOA5 gene leads to 4-fold increased serum TG concentrations in mice and were decreased by 65% by overexpression of the human APOA5 gene \[[@B6], [@B15]\]. The role of APOA5 gene polymorphisms in CAD has been investigated in many studies and meta-analyses, the results are controversial \[[@B10], [@B16]--[@B19]\]. This discrepancy could be explained by the differences between ethnic populations that can contribute to the variation of prevalence rates of CAD. Furthermore, new studies are continuously being performed to identify whether APOA5 polymorphisms are associated with cardiovascular diseases occurrence \[[@B20]--[@B23]\]. In addition, accumulated data make it possible to conduct cumulative meta-analysis and assess the effects of APOA5 polymorphisms. To date, more than 13 polymorphic sites of APOA5 have been reported \[[@B24]--[@B26]\]. Indeed, several studies in different populations have found the association between the APOA5 polymorphisms and the risk of CAD \[[@B18], [@B20], [@B27]\]. The APOA5 gene polymorphism, c.56C \> G variant located in the exon3, is of a special interest and has been reported to be associated with an increased risk of CAD in multiple ethnic populations probably through its association with hypertriglyceridemia \[[@B3], [@B12]\]. However, there are also discrepant reports of no association between this polymorphism and CAD risk \[[@B28], [@B29]\].

In order to evaluate the associations between APOA5 gene c.56C \> G polymorphism and CAD, we performed a case-control study in a Moroccan population. In addition, we conducted a meta-analysis to confirm the contribution of this APOA5 polymorphism to CAD in various ethnic populations.

2. Material and Methods {#sec2}
=======================

2.1. Study Population {#sec2.1}
---------------------

Study participants were recruited in the Medical Biology Center of Pasteur Institute of Morocco and Ibn Rochd Hospital. The present study involved 122 patients (73 men and 49 women, mean age 60.70 ± 12.86) with coronary artery disease confirmed by coronary angiography, defined as the presence of at least one coronary artery with ≥50% organic stenosis. The study recruited also 134 unrelated non-CAD controls (42 men and 92 women, mean age 50.78 ± 12.08). All subjects were Moroccan adult volunteers and all provided their written informed consents. Participants completed a health and lifestyle questionnaire including sociodemographic characteristics, medical history, physical activity, medication intake, and alcohol and tobacco use. Clinical, biochemical, anthropometric parameters, and CAD risk factors (hypertension and diabetes mellitus) were assessed in both patients and controls. Hypertension was defined as systolic blood pressure \>140 mmHg or/and diastolic blood pressure \>90 mmHg or using antihypertensive drugs. Type 2 diabetes mellitus was diagnosed according to World Health Organization criteria. All women were nonpregnant and nonlactating. Healthy subjects had normal biochemical variables, were nonsmoking, and without history of CAD.

2.2. Biochemical Measurements {#sec2.2}
-----------------------------

Blood samples were collected in EDTA tubes after at least 12 hours of overnight fast, centrifuged, and stored until subsequent laboratory analysis. Fasting plasma glucose, total cholesterol (TC), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C) levels were determined using the VITROS automate analyzer (5.1 FS Chemistry System). Low-density lipoprotein cholesterol (LDL-C) level was calculated according to the Friedewald formula.

Genomic DNA was isolated from peripheral leukocytes using the standard proteinase *K* digestion followed by phenol-chloroform extraction and ethanol precipitation. The c.56C \> G polymorphism was genotyped by PCR-RFLP analysis. PCR reactions were performed in a Biometra thermal cycler, using Taq polymerase (Bioline), and restriction fragments were analyzed by agarose gel migration (3%). Primers, PCR conditions, and RFLP analysis were performed according to a previously published protocol \[[@B30]\].

PCR of 157 bp fragment of the 56C \> G polymorphism was performed using the following oligonucleotides: Forward: 5′- GGC TCT TCT TTC AGG TGG GTCTCCG -3′ and reverse: 5′- GCC TTT CCG TGC CTG GGT GGT -3′. The PCR started with an initial denaturing at 96°C for 5 min, followed by 30 cycles of 96°C for 30 s, 64°C for 30 s, and 72°C for 45 s and then a final extension of 72°C for 10 min. The PCR products were digested for 2 hours at 65°C with TaqI restriction enzyme: the 56C allele presents a TaqI restriction site which is suppressed in the 56G allele \[[@B31]\]. All molecular analyses were performed in the Genomics and Human Genetic Laboratory at Pasteur Institute of Morocco.

2.3. Literature Search Strategy for the Meta-Analysis {#sec2.3}
-----------------------------------------------------

We conducted a comprehensive literature search using PubMed. Articles published up to January 2020 were searched using the following key words: ("coronary heart disease" OR "coronary artery disease" OR "myocardial infarction") AND ("APOA5" OR "apolipoprotein A5" OR "C56G" OR "S19W" OR "rs3135506") AND ("polymorphism" OR "SNP" OR "variant"). References cited in the identified articles were also analyzed to avoid missing any potential articles from the initial search. Data from studies were included in our meta-analysis only if the study met the following criteria: (1) only CAD as the outcome and the investigated variant should be c.56C \> G exclusively or in the same study with other polymorphisms; (2) only the case-control studies were considered; (3) the genotype distribution of CAD cases and controls can be obtained from articles directly or by calculation; (4) the methods of data collection and analysis should be statistically acceptable; and (5) publications that presented data allowing such outcome to be derived were also included.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Clinical and biochemical parameters normally distributed were expressed as means ± standard deviation (SD), and nonnormally distributed data were expressed as median (Interquartile range) while qualitative parameters were expressed as frequencies. Student\'s *t*-test was applied for comparison of quantitative traits that follow a normal distribution. Otherwise, we used the Mann--Whitney test. The Hardy--Weinberg equilibrium (HWE) analysis of the genotyped SNP was performed using an exact test, available in the R package "compareGroups." The R package "SNPassoc" was used to examine the association between CAD and APOA5 genotypes. A *P* value less than 0.05 was considered statistically significant.

Furthermore, Review Manager 5.3 (The Cochrane Collaboration) was used to elaborate meta-analysis results. Heterogeneity between studies was assessed using the chi-square-based *Q*-test, and the significance was fixed to *P* \< 0.10. The inconsistency index *I* \[[@B2]\] was also calculated to evaluate the variation caused by the heterogeneity. The possible publication bias was estimated using funnel plot. The R software was used to calculate *P* values of Egger\'s test.

3. Results {#sec3}
==========

3.1. Subjects\' Characteristics {#sec3.1}
-------------------------------

Clinical characteristics and lipid parameters of patients with CAD and controls are presented in [Table 1](#tab1){ref-type="table"}. As expected, triglycerides level (TG), glycemia (Gly), systolic blood pressure (SBP), and LDL-C were significantly higher among CAD patients than controls (*P* values \<0.001). There were also significant differences in total cholesterol (TC) and diastolic blood pressure (DBP). No significant differences were found in body mass index (BMI) and HDL-C between both groups.

3.2. Association Analysis {#sec3.2}
-------------------------

We performed a case-control-based association analysis of the c.56C \> G polymorphism with CAD ([Table 2](#tab2){ref-type="table"}). The genotype distribution of the studied variant was in HWE (*P* value \>0.05). Logistic regression analysis adjusted for sex, age, BMI, and smoking showed a significant association between the c.56C \> G polymorphism and CAD susceptibility under co-dominant, recessive, and log-additive models.

3.3. Comparisons of Clinical and Biochemical Parameters between APOA5 Genotypes {#sec3.3}
-------------------------------------------------------------------------------

We compared biological and clinical traits between APOA5 genotypes under homozygote and heterozygote codominant, dominant, and recessive genetic models. The APOA5 c.56C \> G polymorphism was significantly associated with increased levels of systolic and diastolic blood pressure, triglycerides, glycemia, and total cholesterol ([Table 3](#tab3){ref-type="table"}).

3.4. Meta-Analysis {#sec3.4}
------------------

The literature search identified 109 potentially relevant articles, the publication date of these studies ranged from 2004 to 2018, forty-six of which were excluded after initial screening of title and abstract. The full text of remaining 67 studies was reviewed, and 56 additional articles were excluded because they did not meet the inclusion criteria. Finally, 11 studies were included in our meta-analysis in addition to our case-control study, with a total of 5705 CAD patients and 7242 controls. A flow chart of study selection is shown in [Figure 1](#fig1){ref-type="fig"} and characteristics of included are presented in [Table 4](#tab4){ref-type="table"}.

Meta-analysis of the 12 genetic association studies and publication bias analyses are summarized in [Table 5](#tab5){ref-type="table"}. The c.56C \> G polymorphism was significantly associated with genetic predisposition to CAD under recessive mode of inheritance (OR = 3.39; 95% CI = \[1.77--6.50\]; *P* value \<0.001). Moreover, using the homozygote codominant model, the GG genotype was significantly associated with susceptibility to CAD compared to the CC genotype (OR = 3.96; 95% CI = \[2.44--6.45\]; *P* value \<0.001). A random-effect model was used to estimate pooled odds ratios if considerable heterogeneity was detected (*Q*-statistic: *P* \< 0.10 or *I*^2^ \> 50%). Otherwise, a fixed-effect model was used (*Q*-statistic: *P* \> 0.10 and *I*^2^ \< 50%). No significant publication bias was shown using both funnel plot analyses and Egger\'s test in all tested genetic models.

4. Discussion {#sec4}
=============

Coronary artery disease (CAD) is a multifactorial disease in which atherosclerotic plaque accumulates inside the coronary arteries resulting in myocardial infarction and mortality. Hypertriglyceridemia is significantly associated with the increased risk of CAD, as elevated levels of triglycerides (TG) may lead to plaque formation \[[@B39]--[@B41]\]. The APOA5/4/C3/A1 gene cluster on chromosome 11q23 plays an important role in TG regulation; particularly variants occurring in the APOA5 gene have been extensively analyzed for their relationship with TG metabolism and cardiovascular diseases susceptibility \[[@B34], [@B36], [@B42]\]. Therefore, the present study was designed to examine the implication of the c.56C \> G APOA5 variant as a coronary artery disease risk factor in the Moroccan population.

Logistic regression analysis adjusted for possibly confounding factors (sex, age, BMI, and smoking) showed a significant association between c.56C \> G APOA5 variant and coronary artery disease. Various studies were performed in different populations in order to assess the association between this variant and CAD, but the results are conflicting. Consistent with our findings, the c.56C \> G SNP was significantly associated with increased risk of CAD in a previous study on Chinese patients \[[@B33]\]. Similarly, a significant susceptibility to CAD was detected in subjects from Czech Republic carrying the rare allele of the c.56C \> G SNP \[[@B32]\]. In contrast, two studies including patients of Italian and French origins failed to detect a relationship between c.56C \> G SNP risk allele and CAD \[[@B28], [@B35]\].

Currently, the biological mechanisms by which the c.56C \> G (S19W) missense polymorphism regulates the plasma triglyceride levels are not sufficiently well elucidated and need further research. Talmud et al. suggested that the c.56C \> G variant may have functional effects on the APOA5 protein \[[@B30]\]. The substitution of hydrophilic serine to hydrophobic tryptophan residue could affect APOA5 signal peptide activity with the endoplasmic reticulum, suggesting that this amino acid change is potentially functional and may reduce the amount of functioning protein \[[@B30]\]. Transgenic and gene knockout mice showed an inverse regulation between APOA5 expression and plasma TG levels, supporting a role for the apolipoprotein A5 in human triglycerides secretion \[[@B6]\].

In the present study, the c.56C \> G variant showed significant association with plasma triglyceride levels. We observed elevated triglyceride levels in subjects carrying the GG genotype compared to noncarriers. Similarly, TG levels were also significantly higher in Turkish subjects carrying the GG genotype \[[@B43]\]. The rare allele of the c.56C \> G polymorphism was significantly associated with increased TG levels in previous studies on subjects from Spain \[[@B44]\], United Kingdom \[[@B30]\], and Brazil \[[@B3]\].

In contrast, we did not find any relationship between HDL-C levels in subjects carrying the G allele compared to noncarriers, which is consistent with findings reported by other studies \[[@B29], [@B33], [@B36]\]. A recent study showed that elevated levels of fasting TG are significantly associated with increased risk of myocardial infarction and gradually decreased levels of HDL-C \[[@B45]\]. Despite this negative correlation that have been shown between HDL-C and plasma TG in several studies, there was no evidence of any association between decreased HDL-C levels and the APOA5 G allele \[[@B35]\].

The association between the c.56C \> G polymorphism and susceptibility to CAD remains controversial. To elucidate this discrepancy, we performed a meta-analysis considering the data from all studies exploring the association between this APAO5 variant and increased risk of CAD in various ethnicities.

Several studies were interested in gathering data on APOA5 polymorphisms implication in CAD susceptibility \[[@B18], [@B46]--[@B50]\]. Our meta-analysis showed a strong association between the c.56C \> G polymorphism and the risk of CAD under the recessive and homozygote codominant genetic models. Similarly, a previous meta-analysis based on 5 association studies reported a strong association of the c.56C \> G polymorphism and genetic predisposition to CAD under the recessive genetic model \[[@B46]\]. In contrast, Zhou and colleagues performed a meta-analysis including 7 studies, and they did not find any significant implication of the c.56C \> G variant in CAD susceptibility \[[@B19]\].

Our work may have some limitations. Firstly, CAD is a multifactorial and polygenic disorder involving complex genes and environmental interactions that were not evaluated. Secondly, articles in other languages than English were not included in this meta-analysis. That may result in a bias, although funnel plots and Egger\'s test showed no significant bias. Lastly, we performed a comprehensive literature research to collect all eligible studies; however, the number of included studies was not large. Thus, further genetic association studies are needed to evaluate the relationship between this APOA5 variant and CAD risk in different populations.

5. Conclusion {#sec5}
=============

In summary, the current case-control study showed that the 56C \> G polymorphism is a CAD risk factor in the Moroccan population. In addition, our results clarify that the overall conclusion of the literature to data indicates a significant association between 56C \> G polymorphism and CAD in different populations, supporting our case-control study results. An improved case-control investigation with larger sample sizes and a balanced gender structure could provide sufficient statistical power to obtain a clear conclusion on the contribution of the 56C \> G APOA5 polymorphism in CAD susceptibility.
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###### 

The funnel plots of the meta-analysis showing the association of the C56G polymorphism with CAD under all studied inheritance models(recessive, dominant, homozygote co-dominant, heterozygote co-dominant and allelic models).

###### 

Click here for additional data file.

![Flow chart of the study selection process for eligible studies.](CRP2020-5981971.001){#fig1}

###### 

Comparison of clinical and biochemical characteristics between controls and patients with CAD.

                  Controls (*n* = 134)   CAD (*n* = 122)        *P* value
  --------------- ---------------------- ---------------------- -----------
  Age (years)     50.78 ± 12.08          60.70 ± 12.86          \<0.001
  Sbp (mmgHg)     122 \[118--126\]       140 \[123--160\]       \<0.001
  Dbp (mmgHg)     77.49 ± 7.97           80.83 ± 12.99          0.015
  BMI (kg/m^2^)   26.49 ± 4.11           25.68 ± 4.73           0.148
  TG (mg/dl)      97 \[71.25--122.5\]    156 \[105.5--179.2\]   \<0.001
  LDL-C (mg/dl)   115 ± 28               141 ± 46               \<0.001
  HDL-C (mg/dl)   51 ± 13                50 ± 18                0.660
  Gly (mg/dl)     89 \[85--99\]          119 \[94--153\]        \<0.001
  TC (mg/dl)      188 ± 28               205 ± 53               0.002
  Diabetes (%)    0 (0%)                 38 (31%)               \<0.001
  Smoking (%)     0 (0%)                 21 (31%)               \<0.001

Sbp: systolic blood pressure, Dbp diastolic blood pressure, BMI: body mass index, TG: Triglycerides, LDL: low-density lipoprotein cholesterol, HDL: high-density lipoprotein cholesterol, Gly: glycemia, TC: serum total cholesterol. Data are expressed as mean ± standard deviation or median (interquartile range) for quantitative parameters and as frequencies for qualitative parameters.

###### 

Genotypic distribution of the 56C \> G variant in patients with coronary artery disease and control subjects.

  Genetic model   Controls *n* (%)   Cases *n* (%)   Codominant              Dominant   Recessive           Log-additive                                                       
  --------------- ------------------ --------------- ----------------------- ---------- ------------------- -------------- --------------------- --------- ------------------- -------
  C/C             117 (87.3)         93 (76.2)       1.00                    0.001      1.90 (0.87--4.15)   0.107          13.14 (2.56--67.47)   \<0.001   2.10 (1.19--3.69)   0.008
  C/G             15 (11.2)          13 (10.7)       0.80 \[0.30--2.11\]                                                                                                        
  G/G             2 (1.5)            16 (13.1)       12.85 \[2.49--66.22\]                                                                                                      
  MAF             0.071              0.184                                                                                                                                      
  HWE *P*value    0.125              \<0.001                                                                                                                                    

MAF: minor allele frequency, HWE: *P* value for Hardy--Weinberg equilibrium.

###### 

Association between APOA5 variant genotypes and clinical and biochemical parameters.

  Parameter       Genotypes          *P* value          *P* value          *P* value   *P* value           
  --------------- ------------------ ------------------ ------------------ ----------- ----------- ------- ---------
                  (*n* = 210)        (*n* = 28)         (*n* = 18)                                          
  Dbp (mmgHg)     78.57 ± 9.78       79.18 ± 16.79      84.94 ± 8.73       0.779       0.008       0.102   0.016
  Sbp (mmgHg)     123 \[119--133\]   127 \[120--146\]   147 \[135--175\]   0.285       \<0.001     0.005   \<0.001
  BMI (kg/m^2^)   26.18 ± 4.22       25.66 ± 4.99       25.93 ± 5.84       0.550       0.821       0.568   0.866
  LDL (mg/dl)     126 ± 39           121 ± 35           150 ± 50           0.531       0.064       0.327   0.057
  HDL (mg/dl)     51 ± 16            50 ± 13            45 ± 16            0.667       0.131       0.218   0.132
  TC (mg/dl)      194 ± 40           192 ± 37           230 ± 64           0.816       0.033       0.125   0.032
  TG (mg/dl)      113 \[75--151\]    105 \[76--133\]    212 \[158--273\]   0.477       \<0.001     0.021   \<0.001
  Gly (mg/dl)     98 \[88--119\]     92 \[90--95\]      115 \[99--181\]    0.281       0.018       0.557   0.012

Sbp: systolic blood pressure, Dbp: diastolic blood pressure, BMI: body mass index, TG: triglycerides, LDL: low-density lipoprotein cholesterol, HDL: high-density lipoprotein cholesterol, Gly: glycemia, TC: serum total cholesterol.

###### 

Characteristics of studies included in the meta-analysis.

  Study                             Population   Subjects   Sex (M/F)   Average age (years)   Genotypes/alleles c.56C \> G                                                                                           
  --------------------------------- ------------ ---------- ----------- --------------------- ------------------------------ --------------- -------------- ----- ----- ----- ------ ----- ------ ----- ----- ------ ------
  Hubacek et al. \[[@B32]\]         Caucasians   435        2559        435/0                 1191/1368                      51.1 ± 7.6      49             369   56    10    794    76    2198   352   9     4748   370
  Liu et al. \[[@B33]\]             China        483        502         285/198               276/226                        54.2 ± 6.3      54.4 ± 5.8     439   43    1     921    45    502    0     0     1004   0
  Ruiz-Narváez \[[@B34]\]           Costa Rica   1703       1703        1260/443              1260/443                       58 ± 11         58 ± 11        NA    NA    NA    3079   327   NA     NA    NA    3059   347
  Dallongeville et al. \[[@B35]\]   France       429        458         442/0                 475/0                          35--64          35--64         368   56    5     792    66    414    44    0     872    44
  Martinelli et al. \[[@B28]\]      Italy        669        244         544/125               168/76                         60.7 ± 9.3      58.7 ± 12.7    605   59    5     1269   69    219    25    0     463    25
  Soufi et al. \[[@B36]\]           German       334        167         276/58                109/58                         60 ± 10         54 ± 12        286   43    5     615    53    154    13    0     321    13
  Prochaska et al. \[[@B29]\]       Brazil       180        170         62.4/37.6             55.9/44.1                      60.1 ± 12.5     58.3 ± 11.3    157   23    0     337    23    145    25    0     315    25
  Iqbal et al. \[[@B26]\]           Pakistan     192        192         145/47                130/62                         55.6 ± 11.1     53.4 ± 12.4    NA    NA    NA    127    257   NA     NA    NA    100    284
  Srivastava et al. \[[@B37]\]      India        304        304         259/45                240/64                         56.66 ± 12.16   54.35 ± 9.65   174   106   24    454    154   213    79    12    505    103
  Kashyap et al. \[[@B16]\]         India        512        272         448/64                162/110                        58.1 ± 10.2     50.3 ± 11.1    505   6     0     1016   6     266    6     0     538    6
  Wang et al. \[[@B38]\]            USA          342        537         222/120               260/277                        39.8 ± 5.1      53.4 ± 12.1    1     25    316   27     657   0      58    479   58     1016
  This study                        Morocco      122        134         73/49                 42/92                          51 ± 12.08      61 ± 12.86     93    13    16    199    45    117    15    2     249    19

NA: missing data in the publication.

###### 

Association between c.56C \> G variant and risk of CAD in the meta-analysis.

  Model                              Number of included studies^*∗*^   Test of association   Test of heterogeneity   Publication bias                           
  ---------------------------------- --------------------------------- --------------------- ----------------------- ------------------ -------- --------- ---- -------
  Recessive model (CC + CG vs. GG)   10                                3.39                  \[1.77--6.50\]          \<0.001            Random   0.05      50   0.086
  Dominant model (CC vs. CG + GG)    10                                1.35                  \[0.97--1.87\]          0.07               Random   0.001     67   0.700
  Co-dominant model (CC vs. CG)      10                                1.17                  \[0.84--1.63\]          0.35               Random   0.002     65   0.798
  Co-dominant model (CC vs. GG)      10                                3.96                  \[2.44--6.45\]          \<0.001            Fixed    0.31      15   0.914
  Allele contrast (C vs. G)          12                                1.29                  \[1--1.68\]             0.05               Random   \<0.001   80   0.117

^*∗*^Number of included studies includes our case control study data.
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